On June 23, 2025, X4 Pharmaceuticals, Inc. signed a purchase agreement with Lincoln Park Capital Fund, allowing the company to sell up to $40 million in common stock under specific conditions. The agreement allows for sales of up to 30,000 shares on business days if the stock price meets certain thresholds, increasing to a maximum of 60,000 shares at higher prices.